
Alector starts Phase I study of AL002 for Alzheimer’s disease
Alector has started a Phase I INVOKE clinical study to evaluate AL002 for the treatment of Alzheimer’s disease.
Alector has started a Phase I INVOKE clinical study to evaluate AL002 for the treatment of Alzheimer’s disease.
Thank you for subscribing to Clinical Trials Arena